Table 2: Open in new tab Clinical...

	Total
Baseline
Age at SGLT2i initiation, years	55 (42–65)
Weight, kg	84 (73–98)
BMI, kg/m²	29 (26–33)
Weight classification, N (%)
Underweight	5 (1)
Normal	108 (22)
Overweight	183 (37)
Obesity class I	122 (25)
Obesity class II	45 (9)
Obesity class III	30 (6)
RAS blockade, N (%)
ACEi	225 (46)
ARB	253 (51)
Both	15 (3)
Diuretic, N (%)
None	305 (62)
Thiazide-type/thiazide-like	56 (11)
Loop	69 (14)
Aldosterone antagonist	40 (8)
Combinations of diuretics^a	23 (5)
Maintenance immunosuppression, N (%)	79 (16)
Prednisone	46 (9)
Mycophenolate mofetil	42 (8)
Calcineurin inhibitor	19 (4)
Other^b	14 (3)
Onset of SGLT2i
Type of SGLT2i, N (%)
Dapagliflozin	386 (78)
Empagliflozin	70 (14)
Canagliflozin	37 (8)
Systolic blood pressure, mmHg	134 ± 17
Diastolic blood pressure, mmHg	78 ± 11
Serum creatinine, mg/dL	1.4 (1–1.9)
eGFR, mL/min/1.73m²	56 (39–82)
Serum albumin, g/dL	3.9 (3.5–4.3)
UACR, mg/g^c	1287 (729–2294)
24-h proteinuria, g/day	2.1 (1.2–3.6)
Patients with nephrotic-range proteinuria^d, N (%)	130 (26)

Total

Characteristic

(N = 493)

Baseline

Age at SGLT2i initiation, years

55 (42–65)

Weight, kg

84 (73–98)

BMI, kg/m²

29 (26–33)

Weight classification, N (%)

Underweight

5 (1)

Normal

108 (22)

Overweight

183 (37)

Obesity class I

122 (25)

Obesity class II

45 (9)

Obesity class III

30 (6)

RAS blockade, N (%)

ACEi

225 (46)

ARB

253 (51)

Both

15 (3)

Diuretic, N (%)

None

305 (62)

Thiazide-type/thiazide-like

56 (11)

Loop

69 (14)

Aldosterone antagonist

40 (8)

Combinations of diuretics^a

23 (5)

Maintenance immunosuppression, N (%)

79 (16)

Prednisone

46 (9)

Mycophenolate mofetil

42 (8)

Calcineurin inhibitor

19 (4)

Other^b

14 (3)

Onset of SGLT2i

Type of SGLT2i, N (%)

Dapagliflozin

386 (78)

Empagliflozin

70 (14)

Canagliflozin

37 (8)

Systolic blood pressure, mmHg

134 ± 17

Diastolic blood pressure, mmHg

78 ± 11

Serum creatinine, mg/dL

1.4 (1–1.9)

eGFR, mL/min/1.73m²

56 (39–82)

Serum albumin, g/dL

3.9 (3.5–4.3)

UACR, mg/g^c

1287 (729–2294)

24-h proteinuria, g/day

2.1 (1.2–3.6)

Patients with nephrotic-range proteinuria^d, N (%)

130 (26)

	Total
Baseline
Age at SGLT2i initiation, years	55 (42–65)
Weight, kg	84 (73–98)
BMI, kg/m²	29 (26–33)
Weight classification, N (%)
Underweight	5 (1)
Normal	108 (22)
Overweight	183 (37)
Obesity class I	122 (25)
Obesity class II	45 (9)
Obesity class III	30 (6)
RAS blockade, N (%)
ACEi	225 (46)
ARB	253 (51)
Both	15 (3)
Diuretic, N (%)
None	305 (62)
Thiazide-type/thiazide-like	56 (11)
Loop	69 (14)
Aldosterone antagonist	40 (8)
Combinations of diuretics^a	23 (5)
Maintenance immunosuppression, N (%)	79 (16)
Prednisone	46 (9)
Mycophenolate mofetil	42 (8)
Calcineurin inhibitor	19 (4)
Other^b	14 (3)
Onset of SGLT2i
Type of SGLT2i, N (%)
Dapagliflozin	386 (78)
Empagliflozin	70 (14)
Canagliflozin	37 (8)
Systolic blood pressure, mmHg	134 ± 17
Diastolic blood pressure, mmHg	78 ± 11
Serum creatinine, mg/dL	1.4 (1–1.9)
eGFR, mL/min/1.73m²	56 (39–82)
Serum albumin, g/dL	3.9 (3.5–4.3)
UACR, mg/g^c	1287 (729–2294)
24-h proteinuria, g/day	2.1 (1.2–3.6)
Patients with nephrotic-range proteinuria^d, N (%)	130 (26)

Table 2:

Open in new tab

Clinical characteristics at the time of SGLT2i initiation.

	Total
Characteristic	(N = 493)
Baseline
Age at SGLT2i initiation, years	55 (42–65)
Weight, kg	84 (73–98)
BMI, kg/m²	29 (26–33)
Weight classification, N (%)
Underweight	5 (1)
Normal	108 (22)
Overweight	183 (37)
Obesity class I	122 (25)
Obesity class II	45 (9)
Obesity class III	30 (6)
RAS blockade, N (%)
ACEi	225 (46)
ARB	253 (51)
Both	15 (3)
Diuretic, N (%)
None	305 (62)
Thiazide-type/thiazide-like	56 (11)
Loop	69 (14)
Aldosterone antagonist	40 (8)
Combinations of diuretics^a	23 (5)
Maintenance immunosuppression, N (%)	79 (16)
Prednisone	46 (9)
Mycophenolate mofetil	42 (8)
Calcineurin inhibitor	19 (4)
Other^b	14 (3)
Onset of SGLT2i
Type of SGLT2i, N (%)
Dapagliflozin	386 (78)
Empagliflozin	70 (14)
Canagliflozin	37 (8)
Systolic blood pressure, mmHg	134 ± 17
Diastolic blood pressure, mmHg	78 ± 11
Serum creatinine, mg/dL	1.4 (1–1.9)
eGFR, mL/min/1.73m²	56 (39–82)
Serum albumin, g/dL	3.9 (3.5–4.3)
UACR, mg/g^c	1287 (729–2294)
24-h proteinuria, g/day	2.1 (1.2–3.6)
Patients with nephrotic-range proteinuria^d, N (%)	130 (26)

	Total
Characteristic	(N = 493)
Baseline
Age at SGLT2i initiation, years	55 (42–65)
Weight, kg	84 (73–98)
BMI, kg/m²	29 (26–33)
Weight classification, N (%)
Underweight	5 (1)
Normal	108 (22)
Overweight	183 (37)
Obesity class I	122 (25)
Obesity class II	45 (9)
Obesity class III	30 (6)
RAS blockade, N (%)
ACEi	225 (46)
ARB	253 (51)
Both	15 (3)
Diuretic, N (%)
None	305 (62)
Thiazide-type/thiazide-like	56 (11)
Loop	69 (14)
Aldosterone antagonist	40 (8)
Combinations of diuretics^a	23 (5)
Maintenance immunosuppression, N (%)	79 (16)
Prednisone	46 (9)
Mycophenolate mofetil	42 (8)
Calcineurin inhibitor	19 (4)
Other^b	14 (3)
Onset of SGLT2i
Type of SGLT2i, N (%)
Dapagliflozin	386 (78)
Empagliflozin	70 (14)
Canagliflozin	37 (8)
Systolic blood pressure, mmHg	134 ± 17
Diastolic blood pressure, mmHg	78 ± 11
Serum creatinine, mg/dL	1.4 (1–1.9)
eGFR, mL/min/1.73m²	56 (39–82)
Serum albumin, g/dL	3.9 (3.5–4.3)
UACR, mg/g^c	1287 (729–2294)
24-h proteinuria, g/day	2.1 (1.2–3.6)
Patients with nephrotic-range proteinuria^d, N (%)	130 (26)

Data are presented as mean ± SD, median (IQR) or N (%).

Including combination of loop plus thiazide diuretics (50%), thiazide plus aldosterone antagonist (32%) and loop plus aldosterone antagonist (18%).

Including azathioprine in six patients (1%), belimumab in four (1%), maintenance rituximab in three (0.6%), leflunomide in one (0.2%).

Only available in 378 (77%) patients.

Defined as 24-h proteinuria ≥3.5 g/day.

UACR: urinary albumin-to-creatinine ratio.

This Feature Is Available To Subscribers Only